Roivant Sciences Ltd. (ROIV)
41.48
+6.55
(+18.75%)
USD |
NASDAQ |
Sep 08, 16:00
41.30
-0.18
(-0.43%)
After-Hours: 20:00
Roivant Sciences EPS Diluted (Quarterly) : -0.2634 for June 30, 2026
EPS Diluted (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -0.2634 |
| March 31, 2026 | 0.373 |
| December 31, 2025 | -0.3816 |
| September 30, 2025 | -0.1667 |
| June 30, 2025 | -0.3283 |
| March 31, 2025 | -0.2919 |
| December 31, 2024 | 0.2344 |
| September 30, 2024 | -0.313 |
| June 30, 2024 | 0.1219 |
| March 31, 2024 | -0.1882 |
| December 31, 2023 | 6.035 |
| September 30, 2023 | -0.3951 |
| Date | Value |
|---|---|
| June 30, 2023 | -0.3843 |
| March 31, 2023 | -0.0453 |
| December 31, 2022 | -0.4935 |
| September 30, 2022 | -0.4166 |
| June 30, 2022 | -0.4768 |
| March 31, 2022 | -0.3899 |
| December 31, 2021 | -0.4144 |
| September 30, 2021 | -0.3206 |
| June 30, 2021 | -0.3701 |
| March 31, 2021 | -2.288 |
| March 31, 2020 | -0.2771 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| Oxford Biomedica Plc | -- |
| Bicycle Therapeutics Plc | -0.7224 |
| Arbutus Biopharma Corp. | -0.026 |
| Moderna, Inc. | -1.965 |
| Adaptimmune Therapeutics Plc | -0.1163 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -290.61M |
| Revenue (Quarterly) | 1.442M |
| Total Expenses (Quarterly) | 191.28M |
| Enterprise Value | 26.93B |
| Gross Profit Margin (Quarterly) | 38.70% |
| Profit Margin (Quarterly) | -20.15K% |
| Earnings Yield | -1.06% |
| Normalized Earnings Yield | -2.950 |